Respiratory Syncytial Virus Infections clinical trials

The registry lists 306 studies for Respiratory Syncytial Virus Infections across more than 10 countries. 49 are recruiting or about to start. 273 of them are mainly about Respiratory Syncytial Virus Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Get an email when these change. Save the Respiratory Syncytial Virus Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 200
Recruiting: 29
Terminated: 22
Active, not recruiting: 19
Not yet recruiting: 17
Status unknown: 9

Phase

Phase 1: 107
Phase 2: 81
Phase 3: 47
Phase 4: 3

Where

United States: 145
United Kingdom: 53
Australia: 44
Spain: 39
France: 31
Canada: 30

Who runs them

GlaxoSmithKline (40) · National Institute of Allergy and Infectious Diseases (NIAID) (23) · Enanta Pharmaceuticals, Inc (14) · Pfizer (13) · MedImmune LLC (10) · Sanofi Pasteur, a Sanofi Company (9) · Gilead Sciences (8) · Shanghai Ark Biopharmaceutical Co., Ltd. (7)

What is being tested here

Drugs under test in Respiratory Syncytial Virus Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Remdesivir	2	0	2
Arexvy	1	15	17
EDP-938	1	0	10
Ziresovir	1	2	7
Abrysvo	1	1	3
Clesrovimab	1	2	3
CHO cell	1	0	1
Nirsevimab	0	3	7
Lumicitabine	0	0	7
Sisunatovir	0	1	6

Coming up

10phase 3 studies under way

23studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Mar 2027A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children · Phase 3 · Simcere Pharmaceutical Co., Ltd
Jun 2027Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections · Phase 3 · Kexing Biopharm Co., Ltd.
Jul 2027Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children · Phase 3 · University of Alabama at Birmingham
Nov 2026Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset · Pfizer
Nov 2026RESCEU: Defining the Burden of RSV Disease · University of Oxford
Dec 2026A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus · Enanta Pharmaceuticals, Inc
Dec 2026Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSV · Assistance Publique - Hôpitaux de Paris
Dec 2026RSV Burden in Outpatient and Hospital Settings · Association Clinique Thérapeutique Infantile du val de Marne
Dec 2026A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease · Shionogi
Dec 2026Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus ) · Tam Anh Research Institute

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger. 13 (45%) take children under 18. 2 (7%) are for women only and 0 (0%) for men only; 8 (28%) take healthy volunteers.

Recruiting studies that take each age, of 29
Age	Women	Men
10	3 (10%)	3 (10%)
18	17 (59%)	15 (52%)
30	17 (59%)	15 (52%)
40	17 (59%)	15 (52%)
50	16 (55%)	14 (48%)
65	18 (62%)	17 (59%)
75	18 (62%)	17 (59%)
85	17 (59%)	16 (55%)

Across all 306 studies, recruiting or not: 66% stop at 75 or younger and 62% at 65; 44% take children; 7% are for women only and 3% for men only; 59% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Respiratory Syncytial Virus Infections studies take

Of 57 phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	8 mo5–17 · 57 studies	6 mo3–12 · 44 studies	—
Phase 1/2	22 mo9–27 · 16 studies	—	—
Phase 2	11 mo5–27 · 37 studies	11 mo5–27 · 32 studies	—
Phase 3	8 mo6–23 · 32 studies	8 mo4–19 · 27 studies	—
Observational	25 mo11–51 · 31 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Newly registered3

Severe Pediatric Respiratory Syncytial Virus Infections Occurring in the Era of Antiviral ProphylaxisOct 26, 2026NCT07893652
Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection.Oct 20, 2026NCT07881991
Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France RegionOct 20, 2026NCT07882186

Studies

Recruiting first, then most recently updated. Showing 50 of 306. Browse all 306 → or search them.